GLP-1 Drugs Are No Riskier Than Other Weight Loss Meds After Bariatric Surgery
GLP-1 receptor agonists showed no increased risk of adverse events compared to other antiobesity medications in patients who had previously undergone bariatric surgery.
Quick Facts
What This Study Found
GLP-1RA use was not associated with higher odds of adverse events compared to FDA-approved non-GLP-1 medications (aOR 1.1, 95% CI 0.5–2.6) or off-label medications (aOR 1.1, 95% CI 0.6–2.3). Notably, starting any antiobesity medication 12 or more months after surgery was associated with dramatically lower risk of adverse events compared to earlier initiation (aOR 0.01, 95% CI 0.0–0.01, p < 0.001).
Key Numbers
Patients had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy. Compared FDA-approved, off-label, and GLP-1RA antiobesity medications.
How They Did This
Single-center retrospective cohort study of 599 patients aged 16-65 who underwent gastric bypass or sleeve gastrectomy and later initiated antiobesity medications. Patients categorized by medication type (GLP-1RA vs. non-GLP-1RA). Primary outcome: adverse event incidence. Univariate and multivariate logistic regression for risk factors.
Why This Research Matters
Many bariatric surgery patients regain weight and need additional medications. Concerns about GLP-1 drug safety in this population — including delayed gastric emptying in an already altered GI anatomy — have limited prescribing. This study provides reassurance that GLP-1 drugs are as safe as alternatives in these patients.
The Bigger Picture
As GLP-1 drugs become first-line weight management tools, understanding their safety in special populations like post-bariatric patients is essential. This study fills a key evidence gap and may encourage more confident prescribing.
What This Study Doesn't Tell Us
Single-center retrospective design with potential selection bias. Only 123 GLP-1 users — may be underpowered for rare events. No specific adverse event breakdown by type. Unable to determine causation. Timing finding (≥12 months safer) may reflect recovery rather than medication timing specifically.
Questions This Raises
- ?Why is starting weight loss medication earlier after surgery associated with more adverse events?
- ?Are there differences in specific adverse event types between GLP-1 and non-GLP-1 medications?
- ?What is the optimal timing and dose for starting GLP-1 drugs after bariatric surgery?
Trust & Context
- Key Stat:
- No increased risk (aOR 1.1) GLP-1 receptor agonists showed the same adverse event rate as non-GLP-1 weight loss medications in post-bariatric surgery patients
- Evidence Grade:
- Rated moderate: retrospective cohort from a single academic center with 599 patients. Adequate for safety signal detection but limited for rare events.
- Study Age:
- Published in 2024. Addresses a contemporary clinical question as GLP-1 drugs are increasingly prescribed to post-bariatric populations.
- Original Title:
- Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.
- Published In:
- Diabetes, obesity & metabolism, 26(9), 3906-3913 (2024)
- Authors:
- Samuels, Jason M(3), Niswender, Kevin D(2), Roumie, Christianne L, Spann, Matthew D, Flynn, C Robb, Ye, Fei, Blankush, Joseph, Irlmeier, Rebecca, Funk, Luke M, Patel, Mayur B
- Database ID:
- RPEP-09198
Evidence Hierarchy
Frequently Asked Questions
Is it safe to take Ozempic after gastric bypass or sleeve surgery?
This study of 599 patients found GLP-1 drugs were no riskier than other weight loss medications after bariatric surgery, especially when started 12 or more months after the procedure.
When is the best time to start weight loss drugs after bariatric surgery?
Waiting at least 12 months after surgery was associated with dramatically fewer side effects compared to starting earlier, regardless of which medication was used.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09198APA
Samuels, Jason M; Niswender, Kevin D; Roumie, Christianne L; Spann, Matthew D; Flynn, C Robb; Ye, Fei; Blankush, Joseph; Irlmeier, Rebecca; Funk, Luke M; Patel, Mayur B. (2024). Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.. Diabetes, obesity & metabolism, 26(9), 3906-3913. https://doi.org/10.1111/dom.15737
MLA
Samuels, Jason M, et al. "Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.." Diabetes, 2024. https://doi.org/10.1111/dom.15737
RethinkPeptides
RethinkPeptides Research Database. "Adverse event comparison between glucagon-like peptide-1 rec..." RPEP-09198. Retrieved from https://rethinkpeptides.com/research/samuels-2024-adverse-event-comparison-between
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.